HXN-1021
/ Earendil Labs
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 10, 2026
Preclinical Characterization of a Potent and Half-life Extended Anti-OX40L Antibody
(AAAAI 2026)
- "In a pharmacokinetics study, HXN-1021 showed a half-life of about 20 days, significantly longer than that of an Amlitelimab analogue, which showed a half-life of approximately 10 days in the same study. Conclusions HXN-1021 is a next-generation, half-life extended anti-OX40L antibody that has the potential to provide sustained therapeutic benefits for patients with atopic dermatitis and other inflammatory and autoimmune diseases. IND-enabling studies for HXN-1021 are currently underway."
Preclinical • Atopic Dermatitis • Dermatitis • Graft versus Host Disease • Immunology • TNFSF4
1 to 1
Of
1
Go to page
1